Literature DB >> 21328174

[New options in the therapy for neovascular age-related macular degeneration: critieria for repeat treatment in anti-VEGF therapy - current supplementary statement of the Retinological Society, The German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany].

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21328174     DOI： 10.1055/s-0029-1246016

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN： 0023-2165            Impact factor:   0.700


× No keyword cloud information.
  4 in total

1.  [Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014].

Authors: 
Journal:  Ophthalmologe       Date:  2015-03       Impact factor: 1.059

2.  Efficacy and safety of a fixed bimonthly ranibizumab treatment regimen in eyes with neovascular age-related macular degeneration: results from the RABIMO trial.

Authors:  Nicolas Feltgen; Thomas Bertelmann; Mirko Bretag; Sebastian Pfeiffer; Reinhard Hilgers; Josep Callizo; Lena Goldammer; Sebastian Bemme; Hans Hoerauf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-01-19       Impact factor: 3.117

3.  [Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme].

Authors:  A Wolf; L Reznicek; J Muhr; M Ulbig; A Kampik; C Haritoglou
Journal:  Ophthalmologe       Date:  2013-08       Impact factor: 1.059

4.  Cooperation of German ophthalmologists in routine care of patients with neovascular age-related macular degeneration: results of the non-interventional BRIDGE study.

Authors:  Joachim Wachtlin; Andreas Ringwald; Tobias Maulhardt; Karin Pohl; Annette Wiedon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-17       Impact factor: 3.117
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.